How Citizen Advocacy Is Driving Real Change in Menopause Policy — State by State
In early February, we wrote for KCM (here and here) that despite all the acrimony in D.C., menopause is among the few policy issues that transcends political lines. To help advance this agenda, we teamed up to publish A Citizen's Guide to Menopause Advocacy, a free digital booklet to mobilize everyday people.
The good news? It's working!
Yes, there remains an avalanche of uncertainty about the future of federally funded research andnational policy, especially around women's health. But, as covered in the Citizen's Guide, state governments offer an important alternate route. Momentum is growing — and fast.
For quick perspective, three states passed menopause laws over the last two years. As of 2024,California's various medical boards — including for doctors, nurses, and physicians' assistants —now can include coursework in menopausal health for continuing professional education requirements. Illinois (in 2023) and Louisiana (in 2024) mandated insurance coverage for someor all menopause treatments. (A bill to require insurance coverage for menopause treatment alsopassed in California last year, only for Governor Newsom to veto it.)
That one-in-four states have proposed menopause laws shows that citizen advocacy works — andlawmakers are listening. Menopause has gone from 'Having a Moment' in 2023, to 'Fueling aMovement' in 2024, to being named on the 'Ones To Watch: Legislation Landscape for 2025'list in 2025. That's progress.
Below is a state-by-state summary of menopause legislation introduced thus far this year. Checkout the non-profit Let's Talk Menopause (on whose board Jen serves) for additional informationand interactive features that make it easy to track progress and speak up and out.
Arizona:
HB 2734 would enable health care providers with tools to educate women on the symptoms of perimenopause and menopause and create informational materials.
California:
AB 432, the Menopause Care Equity Act would mandate comprehensive insurance coverage for menopause treatment; direct the state Medical Board to develop a menopause-specific Continuing Medical Education (CME) curriculum; and require physicians to complete menopause-specific CME if more than 25 percent of their patient population consists of women.
AB 360 would require the state Medical Board to develop and administer menopause training surveys as part of the license renewal process.
Connecticut:
AB 6593 would require the state Department of Public Health to develop and distribute menopause guidelines and educational resources to health care providers, as well as conduct a public awareness campaign to educate residents; it would also mandate health care providers complete at least one CME credit regarding menopause.
Illinois:
SJR0025 would create Menopause Awareness Week on October 12-18, 2025 'to drive legislative action on workforce protections, healthcare equity, and research funding.'
As noted in the Citizen's Guide, HB5295 will expand prior bill mandating treatment coverage for post-hysterectomy patients to include all menopause treatments as of Jan. 1, 2026.
Maine:
LD 1079 would direct the state Department of Health and Human Services to create informational materials on perimenopause and menopause.
Massachusetts:
H 2499 would mandate the state Department of Public Health improve patient and clinician awareness of the menopause transition and assess and improve menopause CME; it would also assess the impact of menopause on the workforce and policies offered by employers (including health insurance coverage of menopause treatments).
Nevada:
SB 297 would designate the month of September as Perimenopause Awareness Month and October as Menopause Awareness Month.
New Jersey:
AB 5278 would mandate comprehensive insurance coverage for perimenopause and menopause care and treatment.
AB 5309/S4147 would permit one to three credits of CME on menopause to be used by physicians for license renewal.
SB 4197/AB 3334 would require employers to allow employees suffering from a range of menstrual disorders (including as a result of perimenopause) to work remotely unless it would create an undue burden for employers.
New York:
AB 5444 would mandate comprehensive insurance coverage for perimenopause and menopause care and treatment.
AB 5436 would help prevent discrimination and increase awareness about menopause and perimenopause.
A01940/SB3908 would amend the workers' compensation law to provide four days of paid leave for menstrual complications, including perimenopause and menopause.
S1720 would establish an awareness campaign on menopause hormone treatment.
Oregon:
HB 3064 would mandate treatment coverage by health plans within the state's reach, such as those insuring many public school employees and state employees.
Pennsylvania:
A Senate memo has been filed to introduce 2025 legislation that would require the state Department of Health and healthcare providers to provide information about menopause and perimenopause; the bill itself is not yet live.
Rhode Island:
S 0361 would extend workplace protections to those experiencing menopause.
Texas:
HB 3961 would require the Department of State Health Services to develop and distribute a menopause educational program, and to post informational materials on the department website.
For all of us committed to women's health, this wave of legislative visibility should fuel our hope that it's worth our effort to fight for bipartisan and meaningful progress.
We stand by what we wrote for KCM just two (albeit long) months ago:
There is a runway for progress if we're committed to fighting for it. And here's why we should: Menopausal women, like our younger counterparts, must be able to make informed choices about our health. We deserve access to affordable, competent medical care and treatment from trained professionals. We have every right and reason to demand lawmakers and leaders invest in solutions that ensure our well-being, our dignity, our humanity. We owe it to ourselves — and to generations to come – to not back away from this cause, but double down in the pursuit.
Jennifer Weiss-Wolf is the executive director of the Birnbaum Women's Leadership Center at NYU Law. Dr. Mary Claire Haver is a board-certified OB/GYN and certified menopause practitioner. They're co-authors of A Citizen's Guide to Menopause Advocacy.
The post How Citizen Advocacy Is Driving Real Change in Menopause Policy — State by State appeared first on Katie Couric Media.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Democratic governors seek to roll back state-funded health care for undocumented immigrants
A trio of states with Democratic governors viewed as potential 2028 presidential candidates have taken steps in recent weeks to freeze or cut government-funded health care coverage for undocumented immigrants. Democratic Govs. Gavin Newsom of California, JB Pritzker of Illinois and Tim Walz of Minnesota have largely attributed the proposals to budget shortfalls stemming from original plans to expand health care to immigrants without legal status. But the moves also occur against the backdrop of broader debate within the Democratic Party over how to handle immigration, an issue that dragged it down in the last election and that President Donald Trump and the GOP have continued to try to capitalize on. The plans, which would scale back health care coverage for undocumented immigrants in the three Democratic-led states just years after it was expanded, have angered progressives and immigrant advocacy groups, who warn the party risks alienating its base — particularly as protests against Trump's deportation plans break out around the country. The latest development came in Minnesota on Tuesday, after both chambers of the Legislature passed a bill to end state-funded health care for undocumented adults. The bipartisan effort advanced through the Republican-controlled House and the Democratic-controlled Senate as part of attempts to balance the state budget. It now goes to Walz, who has said he'll sign it. The bill would end undocumented adults' eligibility for MinnesotaCare — the state-funded health insurance program for low-income residents — effectively reversing one of the signature policy wins Walz secured during a landmark legislative session in 2023, when Democrats were in full control of state government. Undocumented children would remain eligible to enroll in the program under the legislation. In California, Newsom unveiled a budget plan last month that would cut back on health care benefits for undocumented immigrants — a stark reversal from his promises of universal health care for all the state's residents, regardless of their immigration status. Newsom's plan in his 2025-26 budget has called for freezing enrollment for undocumented adults to receive the full scope of the state's Medicaid program, known as Medi-Cal. Newsom's office has said the changes would apply only to new applicants over age 19, that existing enrollees wouldn't be kicked off their plans and that the freeze, which would begin next year, wouldn't apply to people enrolled in limited plans. Newsom's proposed changes also included a new $100 monthly premium for adults 19 and older with 'unsatisfactory immigration status' beginning in 2027. His expansion of Medi-Cal has cost far more than his administration anticipated. Newsom has said the changes will help to balance the state's budget, which has run a multibillion-dollar shortfall that he has blamed on Trump's tariffs, as well as growing costs from higher enrollment in Medi-Cal. Meanwhile, Illinois remains on track by the end of the month to end a program — called Health Benefits for Immigrant Adults — that provides state-funded health care coverage for more than 30,000 low-income adults who are living in the state without documentation. Similarly, the program in Illinois was more expensive than expected when it was created in 2021. Pritzker's latest budget, which the Democratic-led Legislature passed last month, proposed eliminating it by July 1. While the moves would help those states recalibrate their budgets, a sweeping Trump-backed domestic policy bill moving through Congress proposes slashing Medicaid funding for states that provide health care coverage to undocumented immigrants. Trump also signed an executive order this year targeting undocumented immigrants' access to government assistance programs. In response to questions from NBC News, Newsom spokesperson Elana Ross reiterated his statement in his initial announcement of the changes last month that 'instead of rolling back the program — meaning cutting people off for basic care — we're capping it.' Pritzker's office said in an email that 'this year, passing a balanced budget required the difficult decision that reflects the reality of Trump and Republicans tanking our national economy and attempting to strip away healthcare.' A Walz spokesperson didn't respond to questions about Minnesota's plan, which was the result of a compromise after Republican lawmakers had pushed to end the entire MinnesotaCare program. 'No one got everything they wanted,' Walz said last month after he reached a tentative deal with Republicans on the budget, which was finalized in a special session this week. 'There were very difficult conversations about issues that were very dear to each of these caucuses. But at the end of the day, we were able to come to this agreement.' Immigrant advocacy groups have panned the moves, saying they risk further imperiling the broader health care system, and blasted Democrats for succumbing to Trump's attacks. 'We urge state leaders to build on their progress, rather than placing the health of their residents at risk,' said Tanya Broder, the senior counsel for health and economic justice policy at the National Immigration Law Center. 'Particularly as extremist politicians scapegoat and target immigrants, we are counting on state officials to do the right thing and hold the line. 'As states increasingly have recognized, a community's health and well-being depend on ensuring that everyone has access to health care. Immigrants pay billions of dollars in federal, state and local taxes, yet many are excluded from critical health care programs,' she added. 'Terminating state coverage for immigrants will compromise our collective health, as well as the health care infrastructure that serves all of us.' Some progressives questioned whether the moves were part of a broader strategy by the three governors to move to the right on the broader issue of immigration, which polling has shown still remains one of Trump's strongest issues. They said they could face a backlash from their base by departing from positions on supporting immigrant communities and expanding health care. 'It really feeds into the conservative narrative that undocumented immigrants are a drain on our communities,' said Jennifer Driver, a senior director at the State Innovation Exchange, a progressive legislative policy group. 'This assumption that by moving more to the middle or to the right that you're going to recruit some people back — I think it's a miscalculation. 'The frustration that you're seeing in the Democratic base is due to this kind of this waffling, this kind of idea that 'OK, yes, we are progressive — but only in some moments,'' Driver added. Other strategists suggested it remained too early to gauge whether a broader shift was in play as governors and other lawmakers positioned themselves for potential 2028 White House bids, and they emphasized that the threats blue states face from Trump are serious. 'The Trump administration is squeezing the hell out of states,' said Jeff Blodgett, a Minnesota-based Democratic strategist who was a campaign manager for the late Sen. Paul Wellstone and the state director for both of Barack Obama's presidential campaigns. 'There's just a lot of concern about current and future budgets given what the federal government is doing to states.' This article was originally published on
Yahoo
2 days ago
- Yahoo
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources. 'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.' 'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.' About APAPP APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Contacts: APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@ (719) 425-7040 Biodesix:Natalie St. Denis, Director Corporate (720) 925-9285
Yahoo
2 days ago
- Yahoo
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation's first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs LOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients at risk for lung cancer. In this novel partnership, the two organizations will launch new educational resources for Lung Health providers on innovative lung nodule risk assessment testing, such as the Nodify Lung® blood-based tests, or cancer treatment decision support testing, such as the IQLung® blood-based tests. According to the American Lung Association, Lung Cancer is the deadliest of all cancers, killing almost as many Americans annually as breast, prostate, and colon cancers combined. As part of this collaboration, Biodesix and APAPP will introduce new programs to educate and empower providers that practice in diverse care settings, both rural and metropolitan, managing large diverse patient populations, often with minimal resources. 'We are excited to collaborate in building awareness on how to improve patient care and outcomes for earlier detection and diagnosis of lung cancer through Biodesix blood tests,' said Scott Hutton, CEO of Biodesix. 'Sadly, the latest statistics indicate that 1 in 18 Americans will receive a lung cancer diagnosis in their lifetime. We want patients and providers to know that there are diagnostic options available to expedite earlier diagnosis and to personalize treatment decisions.' 'APPs are some of the most patient-centric and patient-driven individuals within the healthcare system,' said Corinne Young, President & Founder, Association of Pulmonary Advanced Practice Providers. 'An important part of supporting patients with lung nodules or with a lung cancer diagnosis is to be educated on the diagnostic tools that can give the patients . APAPP is happy to partner with Biodesix to further our commitment to support our professional members so that they may provide the best patient care options.' About APAPP APAPP is the first association solely focused on Advanced Practice Providers (APPs) working in the realms of pulmonary medicine. For the first time, Nurse Practitioners and Physician Assistants can join together under one membership to work towards a common goal of excellence in pulmonology medicine. About Biodesix Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world's leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit Contacts: APAPP:Corinne Young, MSN, FNP, FCCPPresident & Founder, APAPPcorinne@ (719) 425-7040 Biodesix:Natalie St. Denis, Director Corporate (720) 925-9285Sign in to access your portfolio